Please assess the completion status of the following clinical trial:

Trial Title: Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of Non-Hodgkin's Lymphoma (B- or T-cell) or Hodgkin's lymphoma.~2. Prior Chemotherapy\</= 4 weeks of treatment.~3. Age \>/= 18 years old.~4. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-3.~5. Estimated creatinine clearance \>/= 60 ml/min.~6. Must sign an informed consent form.~Exclusion Criteria:~1. Radiologic evidence of vertebral or hip fracture.~2. BMD T-score less than (i.e., worse than or more negative than) -2.0 at any of the following sites: lumbar spine, femoral neck, or total hip.~3. Patients with secondary non-lymphomatous cancers metastatic to bone. However, other secondary cancers are allowed.~4. Spinal cord compression due to vertebral collapse.~5. Bisphosphonate treatment in the prior 6 months or steroid use (greater than 35 mg of prednisone equivalent steroids) in the prior 3 months. The use of topical, inhaled, or nasal steroids is allowed.~6. Primary hyperparathyroidism.~7. Active osteomalacia.~8. Untreated hypocalcemia (ionized, iCa), Ionized Ca level must be within normal limits prior to enrollment.~9. Untreated secondary hyperparathyroidism, Patients with abnormal parathyroid hormone (PTH) levels may be enrolled as long as they are being treated.~10. Untreated vitamin D deficiency, Vitamin D level may be abnormal and patient may be enrolled as long as they are being treated.~11. Untreated low testosterone (test in men only), testosterone level may be abnormal and patient may be enrolled as long as they are being treated.~12. Paget's disease.~13. Pregnant or breast-feeding.~14. Radiotherapy involving the mandible.~15. Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), or of exposed bone in the mouth, or of slow healing after dental procedures.~16. Recent (within 3 weeks) or planned dental or jaw surgery (e.g.. extraction, implants).~17. Patients with abnormal renal function as evidenced by either a serum creatinine greater than 3 mg/dL or by a calculated creatinine clearance of \< 60 mL/minute.~18. Known hypersensitivity to zoledronic acid or other bisphosphonates.~19. Hypercalcemia: corrected Ca \> 10.2 mg/dL or ionized Ca \> 1.32 mmol/L

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vitamin D + Calcium Carbonate (Type: EXPERIMENTAL): Oral Vitamin D 400 mg daily + Calcium 1200 mg daily
- Vitamin D + Calcium Carbonate + Zoledronic Acid (Type: EXPERIMENTAL): Oral Vitamin D 400 mg daily and Calcium 1200 mg daily; Zoledronic Acid 4 mg/m\^2 intravenous at baseline and 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).